Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vivos Therapeutics Inc (NQ: VVOS )

2.550 +0.050 (+2.00%)
Streaming Delayed Price Updated: 12:20 PM EDT, Oct 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 51,605
Open 2.590
Bid (Size) 2.520 (2)
Ask (Size) 2.540 (1)
Prev. Close 2.500
Today's Range 2.500 - 2.606
52wk Range 1.910 - 48.79
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-78.39%
-78.39%
1 Month
-2.11%
-2.11%
3 Month
+10.87%
+10.87%
6 Month
-18.79%
-18.79%
1 Year
-66.50%
-66.50%

More News

Read More
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Via Benzinga
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Via Investor Brand Network
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000
Via Benzinga
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
Via Benzinga
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update
Via Investor Brand Network
VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot
Via Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Alliance, Private Equity Investment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2024 Financial Report, Operational Update
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
VVOS Stock Earnings: Vivos Therapeutics Reported Results for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2024 Results, Conference Call
Via Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview
Via Investor Brand Network
Topics Product Recall
Exposures Legal Product Safety
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement
Via Investor Brand Network
What's Going On With Vivos Therapeutics Stock?
Via Benzinga
Why Is Laser Photonics (LASE) Stock Up 130% Today?
Via InvestorPlace
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.